Insight into a Patient's Risk for Hereditary Cancer
Vistaseq®
Approximately five to ten percent of cancers are thought to be caused by mutations in genes that are associated with hereditary cancer syndromes.1
VistaSeq® hereditary cancer panels
Genetic mutations have been associated with more than 50 hereditary cancer syndromes.1
Patients with genetic mutations associated with a hereditary cancer syndrome are at a higher risk of developing certain types of cancer than the general population, and usually at an earlier age of onset than is typical.
Genetic testing can help determine whether a patient with a suspected personal or family history of cancer has an inherited gene mutation.
Genetic testing can also help identify family members at risk for developing cancers associated with a hereditary cancer syndrome. VistaSeq® hereditary cancer panels are multi-gene tests that detect inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers.
VistaSeq® hereditary cancer panels are multi-gene tests that detect inherited mutations in genes which have been associated with an increased risk of developing hereditary cancers.
View tests
| VistaSeq Hereditary Cancer Tests by NGS | Test Code | Genes |
|---|---|---|
| Hereditary Cancer - 27 multi-gene panel | 481220 | APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53. |
| Hereditary Cancer Panel without BRCA1/2 Genes | 481240 | APC, ATM, BARD1, BMPR1A, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53. |
| High/Moderate Risk Breast Cancer Panel | 481452 | ATM, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, TP53 |
| Breast Cancer Panel | 481319 | ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHECK2, FAM175A, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 |
| Breast and GYN Cancer Panel | 481341 | ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2,EPCAM, FAM175A, FANCC, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 |
| GYN Cancer Panel | 481330 | BRCA1, BRCA2, CHEK2, EPCAM, MHL1, MSH2, MSH6, MUTYH, PMS2, PTEN, TP53 |
| Lynch Syndrome Panel | 483543 | MLH1, MSH2, MSH6, PMS2, EPCAM |
| MLH1 Comprehensive Analysis | 483496 | MLH1 |
| MSH2 Comprehensive Analysis | 483508 | MSH2 |
| MSH6 Comprehensive Analysis | 483520 | MSH6 |
| PMS2 Comprehensive Analysis | 483532 | PMS2 |
| High Risk Colorectal Cancer Panel | 481352 | APC, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2 |
| Colorectal Cancer Panel | 481363 | APC, ATM, AXIN2, BLM, BMPR1A, BRCA1, BRCA2, CDH1, CDKN2A, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53 |
| APC Comprehensive Analysis | 483484 | APC |
| Pancreatic Cancer Panel | 481385 | APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, TP53, VHL |
| Prostate Cancer Panel | 483555 | ATM, BRCA1, BRCA2, CHEK2, HOXB13 (NGS only), MLH1, MSH2, MSH6, PALB2, PMS2 |
| Endocrine Cancer Panel | 481374 | CDC73, MAX, MEN1, NF1, PRKAR1A, PTEN, RET, SDHB, SDHC, SDHD, TMEM127, TP53, VHL |
| MEN1 Comprehensive Analysis | 483460 | MEN1 |
| RET Comprehensive Analysis | 483472 | RET |
| Brain / CNS / PNS Cancer Panel | 481386 | ALK, APC, MEN1, MLH1, MSH2, MSH6, NBN, NF1, NF2, PHOX2B, PTCH1, PMS2, RB1, SMARCB1, SUFU, TP53, VHL |
| Renal Cell Cancer Panel | 481407 | EPCAM, FH, FLCN, GPC3, MET, MITF (c.952G>A), MLH1, MSH2, MSH6, PTEN, PMS2, SDHB, SDHC, SDHD, TP53, TSC1, TSC2, VHL, WT1 |
Additional hereditary cancer testing options
BRCAssure: Patients with BRCA mutations are at increased risk for breast, ovarian, and other cancers. Knowing your patient’s BRCA mutation status may assist in development of tailored prevention and treatment strategies. For this reason, Integrated Genetics offers a suite of BRCAssure tests to meet patients’ varied needs.
Mutation-specific sequencing: For family testing when a mutation has been specifically identified through one of our VistaSeq panels.
Other testing options
In addition to hereditary cancer screening, we also offer: serum screening and noninvasive prenatal screening (NIPS, sometimes called NIPT or cell-free DNA), including the pioneering whole-genome NIPS; carrier screening, from comprehensive to single-gene; and diagnostic testing that can be used on prenatal and products of conception (POC) samples, as well as pediatric, cord blood or adult samples.
Additional Resources
Genetic Counseling
Genetic counselors translate and communicate genetic information into practical, understandable terms.
Understand Your Results
If you have already had a test, we can answer questions about your results.
Reference
- Genetic Testing for Hereditary Cancer Syndromes. National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-t.... Accessed September 15, 2017.